Latest Articles

  • An Interview With Andreas Eschbach

    How has AI acceptance evolved in the pharmaceutical sector, and what strategies have been most effective in overcoming resistance to AI adoption? read more

  • Future-Proofing Pharmacovigilance in an AI Era

    Clinical research organizations (CROs) are entering an era in which pharmacovigilance systems are doing more than just tracking copious amounts of data. They must also keep pace with evolving regulations, manage the growing volume of adverse event reports, and respond to heightened scrutiny from both regulators and the public. read more

  • Why DSCSA Compliance in 2026 Hinges on Execution, Not Implementation

    After a decade of ramp-up, the era of DSCSA enforcement is no longer theoretical — it’s here. But as we move deeper into this phase of full compliance, the real story unfolds not just in establishing data feeds, but in the operational cracks that persist behind the scenes. read more

  • How Tariffs Could Impact Your Drug Development Supply Chain: Top Five Things to Be Aware Of

    The pharmaceutical industry is entering a period of intensified trade disruption. With new tariffs on imported raw materials, active pharmaceutical ingredients (APIs), and medical components, global supply chains that once prioritized efficiency are now facing rising costs, increased complexity, and growing regulatory risk. For companies developing biologics and Antibody-drug conjugates (ADCs), the impact is particularly acute. read more